Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial

  AIT (n = 26) LED + AIT (n = 29) p
Male 22 (85%) 21 (72%) 0.34
Age 62.3 (5.7) 63.8 (6.7) 0.38
VO2peakffm (mL/kg ffm0.67/min) 124 (24) 126 (25) 0.83
VO2peakbw (mL/kg/min) 20.8 (4.9) 20.6 (5.0) 0.85
Body weight (kg) 96.2 (13.8) 95.5 (10.7) 0.85
Body mass index (kg/m2) 31.5 (29.6; 33.5) 31.3 (29.9; 33.7) 0.85
Body fat mass (kg) 32.6 (7.6) 34.6 (8.0) 0.36
Waist circumference (cm) 110 (10) 108 (7) 0.36
Hip circumference (cm) 111 (8) 110 (7) 0.80
Systolic blood pressure (mmHg) 126 (13) 127 (15) 0.78
Diastolic blood pressure (mmHg) 74 (9.2) 71 (7.7) 0.18
Total cholesterol (mmol/L) 4.3 (0.8) 4.1 (0.7) 0.23
Left ventricular ejection fraction (%) 53 (8) 53 (7) 0.97
Pre-diabetes 21 (81%) 25 (86%) 0.59
Ischaemic aetiology and treatment
 Myocardial infarction 8 (31%) 22 (76%) < 0.001
 Percutaneous coronary intervention 17 (65%) 23 (79%) 0.25
 Coronary artery bypass graft 6 (23%) 6 (21%) 0.83
 Prior cardiac rehabilitation 24 (92%) 21 (72%) 0.06
CCS-class
 0 21 (81%) 23 (79%)  
 I 5 (19%) 6 (21%) 0.89
NYHA-class
 I 21 (81%) 21 (72%)  
 II 5 (19%) 7 (24%) 0.87
 III 0 (0%) 1 (3%)  
Medication
 ACE-I/ARB 15 (58%) 21 (72%) 0.57
 Acetylsalicylic acid 23 (88%) 26 (90%) 1.00
 Beta blocker 12 (46%) 16 (55%) 0.50
 Calcium antagonist 6 (23%) 10 (34%) 0.39
 Statin 25 (96%) 28 (97%) 1.00
 Other cholesterol-lowering drug 5 (19%) 2 (7%) 0.24
  1. Baseline characteristics intention-to-treat population. Categorical data: number (%), normally distributed data: mean (SD), non-normally distributed data: median (IQ-range). p-values: between-group differences
  2. AIT, aerobic interval training; LED, low energy diet; VO2peakbw, peak aerobic capacity corrected for body weight; VO2peakffm, peak aerobic capacity corrected for fat free mass, CCS, Canadian Cardiovascular Society; NYHA, New York Heart Association; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker